Biodexa Pharmaceuticals (BDRX) Change in Receivables (2013 - 2022)
Biodexa Pharmaceuticals (BDRX) posted Change in Receivables of -$1.2 million for Q3 2021, down 83.35% sequentially from -$650982.3 in Q4 2020, and down 92.26% YoY from -$15.4 million in Q3 2020.
Biodexa Pharmaceuticals (BDRX) Change in Receivables (2013 - 2022) Analysis & Trends
Biodexa Pharmaceuticals has reported Change in Receivables for 6 years, with the latest figure at -$1.2 million in Q3 2021.
- Quarterly Change in Receivables fell 92.26% year-over-year to -$1.2 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was -$2.4 million (up 24.94% YoY) and the FY2025 annual result came in at $3.5 million, up 145.2% from the prior year.
- Change in Receivables fell to -$1.2 million in Q3 2021 per BDRX's latest filing, from -$650982.3 in the prior quarter.
- Over five years, Change in Receivables peaked at $78429.2 in Q4 2019 and troughed at -$1.2 million in Q3 2021.
- A 3-year average of -$596736.5 and a median of -$635903.8 in 2020 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2020 and 2021: Change in Receivables sank 930.03% in 2020, then sank 92.26% in 2021.
- Over 3 years, Change in Receivables stood at $78429.2 in 2019, then tumbled by 930.03% to -$650982.3 in 2020, then tumbled by 83.35% to -$1.2 million in 2021.
- According to Business Quant data, Change in Receivables over the past three periods registered -$1.2 million, -$650982.3, and -$620825.2 for Q3 2021, Q4 2020, and Q3 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -262,735.94 |
| Dec 31, 2022 | -262,735.94 |
| Sep 17, 2021 | -1.19 Mn |
| Sep 17, 2021 | -1.19 Mn |
| Dec 31, 2020 | -650,982.34 |
| Dec 31, 2020 | -650,982.34 |
| Sep 10, 2020 | -620,825.22 |
| Sep 10, 2020 | -620,825.22 |
| Dec 31, 2019 | 78,429.22 |
| Dec 31, 2019 | 78,429.22 |
| Dec 31, 2016 | -300,859.79 |
| Dec 31, 2016 | -300,859.79 |
| Dec 31, 2015 | -2.34 Mn |
| Dec 31, 2015 | -2.34 Mn |
| Dec 31, 2013 | -715,630.38 |
| Dec 31, 2013 | -715,630.38 |